Unicycive Theraputics (Nasdaq: UNCY) is a clinical-stage biotechnology company focused on developing kidney medications.
“Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to properly filter waste and excess fluids from the blood. As kidney function declines, patients may develop complications including cardiovascular disease, anemia, bone disorders, and electrolyte imbalances.1-4”
“CKD is commonly caused by diabetes and high blood pressure, although other medical conditions may also contribute to kidney damage over time. As CKD progresses, many patients eventually require dialysis to support kidney function.1-3”
“Common complications of CKD include elevated phosphorus levels (hyperphosphatemia), cardiovascular disease, bone disease, and vascular calcification. Hyperphosphatemia has been associated with increased morbidity and mortality in dialysis patients.1,5-8”
“Patients with advanced or end-stage chronic kidney disease (ESRD) may require dialysis when their kidneys can no longer adequately remove waste products and maintain fluid and electrolyte balance.2,3,9”
“Hyperphosphatemia is a condition characterized by elevated phosphate levels in the blood. It occurs frequently in patients with chronic kidney disease on dialysis because damaged kidneys are unable to effectively remove excess phosphorus from the body. 6,10”
Download this profile and inspect its supporting evidence.